Acufocus KAMRA Corneal Inlay is Now FDA Approved
With FDA approval of the revolutionary KAMRA inlay for the treatment of presbyopia the field of Refractive surgery ushers in the era of PresbyVision correction. For the first time patients will have the opportunity to have a safe technology that will allow for improvement of reading vision without the need of glasses.
The KAMRA corneal inlay enjoys the four cardinal requirements for the safe correction of near vision: 1) It corrects vision at both intermediate and near 2) It does not have an adverse effect on uncorrected distance vision 3) It does not require modification as years pass allowing for the uninterrupted correction of near vision for years to come and 4) It is completely reversible.
KAMRA makes use of small aperture optics allowing for increase of visual depth of field. It is a 3.8 mm diameter, 5 micron thin biocompatible inlay which has a 1.6 mm central opening. The inlay is implanted in the cornea at a depth of 200 microns on the visual axis of the non-dominant eye in a corneal pocket created by the femtosecond laser. The aligned small aperture of the inlay allows for only focused rays of light to enter the pupil thus creating a pinhole effect similar to that derived by a mechanism well known to photographers using high camera F stop to increase depth of field.
Central to successful outcomes patients must be between the ages of 40 and 60 and have good uncorrected distance vision, excellent tear film and no evidence of early cataract formation.The FDA has confirmed that such good candidates enjoy a 97% potential of excellent near visual acuity accompanied by good uncorrected distance vision and excellent depth perception.
Dr. Martin Fox and the Cornea and Refractive Surgery Practice of New York are pleased to report that we have been selected as the first providers of this revolutionary game changer for a generation of baby boomers who now suffer from the loss of the ability to see at near. We are currently accepting patients for consultation.